FT: Regeneron head says weight-loss drugs could cause ‘more harm than good’

US biotech companies are racing to develop treatments that reduce muscle loss caused by popular weight-loss drugs, such as GLP-1s like Ozempic and Wegovy. Regeneron, a leading biotech firm, is testing a drug called trevogrumab to preserve lean muscle while using these medications. Experts warn that the rapid muscle loss associated with GLP-1s may pose long-term health risks, driving the need for safer, muscle-preserving therapies in the growing weight-loss drug market.

Sign up for your early morning brew of the BizNews Insider to keep you up to speed with the content that matters. The newsletter will land in your inbox at 5:30am weekdays. Register here.

By Oliver Barnes in New York

US biotech researches treatments to reduce muscle loss from blockbuster diet medicines

___STEADY_PAYWALL___